Top-quality, rapidly growing European stocks are selling at enticing valuations
Timothy Lewis, portfolio manager at JPMorgan European Growth & Income tells us where he’d put his money
The JPMorgan European Growth & Income trust seeks to invest in quality businesses at attractive valuations. By this, we mean well-run companies that produce strong and sustainable returns on invested capital, where earnings per share translate to tangible cash flow, and also those with management teams making sensible decisions with their capital.
One of the most important attributes we look for in companies is improving operational momentum. One way to assess this is by tracking management guidance and earnings-per-share expectations to see whether they are being upgraded or downgraded over time.
In this regard, Europe provides a rich opportunity, thanks to extreme valuation discounts relative to US peers, the much-improved quality of the firms in our index and the strengthening macroeconomic backdrop. Below are three long-standing holdings in the trust, firms that have displayed strong operating momentum for some time and should be able to continue that performance in the future.
Subscribe to MoneyWeek
Subscribe to MoneyWeek today and get your first six magazine issues absolutely FREE
Sign up to Money Morning
Don't miss the latest investment and personal finances news, market analysis, plus money-saving tips with our free twice-daily newsletter
Don't miss the latest investment and personal finances news, market analysis, plus money-saving tips with our free twice-daily newsletter
A monumental medical leap forward
Novo Nordisk (Copenhagen: NOVO-B) is unique in the pharmaceuticals sector in that it has been almost completely focused on insulin and diabetes for more than a hundred years. It has leveraged its strength in diabetes care into a leading position in the interrelated issue of obesity. Obesity has posed significant challenges for medical practitioners worldwide. Despite advances in healthcare, effective treatment options for obesity have been limited, often culminating in surgical interventions as a last resort.
However, the introduction of Novo Nordisk’s pioneering new drug Wegovy represents a monumental leap forward in the realm of weight-loss treatments. With efficacy levels comparable to surgical procedures, but with significantly reduced risks, Wegovy has emerged as a game-changer in the fight against obesity. Patients’ interest in this revolutionary new drug has continued to exceed expectations, leading to strong operating momentum for the business, but with a market opportunity that can justify sustained growth.
As interest rates have normalised over the past few years, Italy’s UniCredit (Milan: UCG) has experienced an expansion in net-interest margins. This uptrend has resulted in frequent upgrades to earnings forecasts, supporting the sector’s robust performance amid changing market conditions. But valuations for banks such as UniCredit remain compelling, offering an attractive entry point for investors.
Furthermore, thanks to strong capital positions, banks are able to return cash to shareholders through dividends and share buybacks. This shareholder-friendly approach underscores UniCredit’s commitment to delivering long-term value and solidifies its position as an enticing opportunity within the banking sector.
Pioneering Publicis
Ten years ago, Publicis (Paris: PUB) began a journey to lead the advertising industry in data and technology, which included two large acquisitions, Epsilon and Sapient. That journey hasn’t been without bumps in the road, with Covid, a challenging macro-environment and the integration of these two acquisitions to navigate.
However, Publicis is now in a stronger position and has emerged into a much more supportive economic backdrop. It has elevated itself into a “transformation partner” that is data-driven and puts technology first, and which is better able to meet clients’ needs and win market share. Publicis is now the standout leader in the field and looks set to continue that growth.
This article was first published in MoneyWeek's magazine. Enjoy exclusive early access to news, opinion and analysis from our team of financial experts with a MoneyWeek subscription.
Tim Lewis, Executive Director, is a portfolio manager within the J.P. Morgan Asset Management International Equity Group, based in London. He has a particular focus on core Europe mandates. An employee since 2013, Tim joined the firm as a graduate trainee. He obtained a BA in Business and Economics at Trinity College Dublin, and an MSc in Behavioural Economics from the University of Nottingham and is a CFA charterholder.
-
Investing in property: why it is still a good diversifier for the long-term
The fundamental case for property as an asset class remains intact. While the sector has been overshadowed by relatively strong returns from equities and bonds, there is still a strong case for investing in property for the long-term, ii’s head of fund research, Dzmitry Lipski, argues
By Dzmitry Lipski Published
-
The areas worst-hit by the furnished holiday lets tax clampdown
News Holiday home owners are preparing for the end of the popular furnished holiday lets tax regime. We reveal the regions most affected and how to prepare.
By Marc Shoffman Published
-
Energy investment is essential for AI and sustainability
Energy investment is vital to drive an AI revolution or green boom. So, why does the sector remain unloved?
By Cris Sholto Heaton Published
-
Top infrastructure stocks to buy
Matthew Norris, director of Real Estate Securities at Gravis Advisory Limited picks three infrastructure stocks to buy
By Matthew Norris Published
-
Meta’s AI splurge rattles investors
Meta's decision to join the AI race is driving investors away
By Dr Matthew Partridge Published
-
Is it a good time to invest in the UK?
Temple Bar Investment Trust is a diversified bet on British equities and looks excellent value, says Max King
By Max King Published
-
AstraZeneca CEO’s £1.8mn pay rise approved despite shareholder opposition
AstraZeneca hiked its dividend to persuade shareholders to accept CEO Pascal Soriot’s pay rise. Is he worth his salary?
By Dr Matthew Partridge Published
-
Adidas, Nike or Jordans - could collectable trainers make you rich?
The right pair of trainers can fetch six figures. Here's how you can start collecting vintage Adidas, Nike or Jordans now
By Chris Carter Published
-
The industry at the heart of global technology
The semiconductor industry powers key trends such as artificial intelligence, says Rupert Hargreaves
By Rupert Hargreaves Published
-
Three emerging Asian markets to invest in
Professional investor Chetan Sehgal of Templeton Emerging Markets Investment Trust tells us where he’d put his money
By Chetan Sehgal Published